Clinical Trial Update: BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BIO-K+ CL1285 for prevention of recurrent Clostridioides difficile infection has been suspended, with no results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• BIO-K+ CL1285

Snippet

Sponsor: Bio-K Plus International Inc. | Conditions: Recurrent Clostridium Difficile Infection | Phase 3 | Status: SUSPENDED